Lactic acid ( DrugBank: Lactic acid )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
265脂肪萎縮症3
299嚢胞性線維症2

265. 脂肪萎縮症


臨床試験数 : 116 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00126308
(ClinicalTrials.gov)
November 20051/8/2005Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial LipoatrophyA Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH)HIV-Associated Lipodystrophy;HIV InfectionsDevice: poly-L-lactic acidKirby InstituteThe University of New South Wales;Abbott;Bristol-Myers Squibb;Gilead Sciences;GlaxoSmithKline;Merck Sharp & Dohme Corp.;Hoffmann-La Roche;AIDS Council of New South WalesTerminated18 YearsN/ABoth100Phase 4Australia
2NCT00202228
(ClinicalTrials.gov)
July 200213/9/2005Lactate Metabolism Study in HIV Infected PersonsLactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation.HIV Infections;AIDS;Lactic Acidosis;LipodystrophyDrug: cofactor supplementation (thiamine, riboflavin, L-carnitine)Queen's UniversityOntario HIV Treatment NetworkCompleted18 YearsN/ABoth30Phase 4Canada
3NCT00005764
(ClinicalTrials.gov)
May 200030/5/2000A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive PatientsGlaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)HIV Infections;LipodystrophyDrug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: LamivudineGlaxo WellcomeNULLCompleted18 YearsN/ABoth100Phase 4United States

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-015875-28-IT
(EUCTR)
07/10/200922/10/2009Modulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora - Role of intestinal microflora in infants with Cystic FibrosisModulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora - Role of intestinal microflora in infants with Cystic Fibrosis infants with cystic fibrosis
MedDRA version: 9.1;Level: SOC;Classification code 10017947
MedDRA version: 9.1;Classification code 10038738
INN or Proposed INN: Lactic acid producing organismsUNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO IINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
2EUCTR2009-011289-27-IT
(EUCTR)
22/04/200927/04/2009Probiotics in Cystic Fibrosis - NDProbiotics in Cystic Fibrosis - ND Cystic Fibrosis Patients
MedDRA version: 9.1;Level: SOC;Classification code 10017947
INN or Proposed INN: Lactic acid producing organismsUNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO IINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy